A Case of Neuroleptic Malignant Syndrome After COVID-19 Vaccination and Possible Mechanisms of Vaccines in the Formation of This Syndrome
Yükleniyor...
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Taylor & Francis
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Neuroleptic malignant syndrome COVID-19 Vaccine Fatal Complication
Neuroleptic malignant syndrome is characterized by muscle stiffness, hyperthermia, autonomic dysfunction, elevation in serum creatine phosphokinase, and changes in consciousness, which usually occur due to the side effects of life-threatening neuroleptic and antipsychotic drugs, and it can cause high mortality. A few cases of neuroleptic malignant syndrome associated with coronavirus disease 2019 infection and vaccination have been reported in the literature. Our case presented with epileptic seizure and neuroleptic malignant syndrome signs 10 days after receiving a single dose of the BNT162b2 vaccine when under low-dose olanzapine treatment with a diagnosis of autism and epilepsy. According to the laboratory test, the creatine kinase value was very high, there was hyponatremia, and the iron value was low. The patient died. Our aim in reporting this case is to draw attention to the possibility that coronavirus disease 2019 vaccines may trigger neuroleptic malignant syndrome, which can be a fatal complication in patients taking antipsychotics, albeit very rare among the large vaccinated population.
Neuroleptic malignant syndrome is characterized by muscle stiffness, hyperthermia, autonomic dysfunction, elevation in serum creatine phosphokinase, and changes in consciousness, which usually occur due to the side effects of life-threatening neuroleptic and antipsychotic drugs, and it can cause high mortality. A few cases of neuroleptic malignant syndrome associated with coronavirus disease 2019 infection and vaccination have been reported in the literature. Our case presented with epileptic seizure and neuroleptic malignant syndrome signs 10 days after receiving a single dose of the BNT162b2 vaccine when under low-dose olanzapine treatment with a diagnosis of autism and epilepsy. According to the laboratory test, the creatine kinase value was very high, there was hyponatremia, and the iron value was low. The patient died. Our aim in reporting this case is to draw attention to the possibility that coronavirus disease 2019 vaccines may trigger neuroleptic malignant syndrome, which can be a fatal complication in patients taking antipsychotics, albeit very rare among the large vaccinated population.
Açıklama
İrem Taşcı, Department of Neurology, Malatya Turgut Özal University Medical School, Malatya, Turkey.
Kerim Uğur, Department of Psychiatry, Malatya Turgut Özal University Medical School, Malatya, Turkey.
Formerly known as:Klinik Psikofarmakoloji Bulteni
Received: November 8, 2021 Accepted: February 28, 2022
Formerly known as:Klinik Psikofarmakoloji Bulteni
Received: November 8, 2021 Accepted: February 28, 2022
Anahtar Kelimeler
Neuroleptic malignant syndrome, COVID-19, Vaccine, Fatal, Complication
Kaynak
Psychiatry and Clinical Psychopharmacology
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
32
Sayı
1
Künye
Taşcı, İ., & Uğur, K. (2022). A Case of Neuroleptic Malignant Syndrome After COVID-19 Vaccination and Possible Mechanisms of Vaccines in the Formation of This Syndrome. Psychiatry and Clinical Psychopharmacology. 32(1) 89-92.
